That matters because this paper was not really a muscle mass paper, even if it gets cited in articles discussing muscle
Bevacizumab and paclitaxelcarboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
However, the results of clinical trials suggest that the characteristics of the cardiorenal protective effects achieved by these drugs differ slightly, and consensus for their use and evidence for their optimal use and combined benefits are still lacking
Many people choose it because its selective, gentle, and less likely to cause unwanted hormonal spikes
FDA-approved GLP-1 and related medications illustrate why medication-specific instructions matter